Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

With a 25% share of the organized eye care market and a proven track record, Dr. Agarwal's Health Care IPO marks a significant moment for the specialized healthcare sector. However, a high premium may ...

Chart 1: U.S. leads global IPO activity in 2024, followed by Asian markets Since most countries have very different sized economies and stock markets, it’s a little unfair to compare countries ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Broader markets also mirrored the benchmarks as the Nifty Smallcap100 and Nifty Midcap100 indices ended down by 3.84 per cent ...

Among its other ratings Dave has an 81 EPS Rating out of 99, and a best-possible 99 Relative Strength Rating. Additionally it ...

Dr Agarwals' Health Care shares debuted on BSE today at a 1.27% discount, listing at Rs 396.90 per share against the IPO ...

The Bay Area-based biotech revealed the planned IPO in a Jan. 7 filing with the Securities and Exchange Commission but did not divulge how many shares it plans to offer nor at what price.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this respect, BPCL Board has given in-principle approval for the IPO, subject to regulatory and ... pattern known as Insider bar on the daily chart. As long prices hold 182 levels one can ...